PerformRx

Belkins
Formed in 1999, PerformRx, LLC is a URAC accredited pharmacy benefits manager servicing lines of business including Medicaid, Medicare, and Commercial markets. A large percentage of the staff at PerformRx are pharmacists and pharmacy technicians. This ensures that the company maintains a culture of clinical influence and care throughout each business area. Clients receive a personalized solution designed to understand their benefit and meet their needs. This includes offering clients standalone products and services as well as full pharmacy benefit management. PerformRx ensures these solutions by utilizing technology that adapts to specific member populations and changes in the health care landscape.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BEIGENE REPORTS POSITIVE PHASE III INTERIM ANALYSIS FOR LUNG CANCER DRUG

MedCity News | April 14, 2020

news image

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with ...

Read More

PHARMACY MARKET

YANGTZE RIVER PHARMACEUTICAL GROUP SELECTS TRACELINK PLATFORM FOR GLOBAL COMPLIANCE

Yangtze River Pharmaceutical, TraceLink | May 06, 2021

news image

TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, incl...

Read More

PHARMA TECH

CORNING ACCELERATES DELIVERY OF LIFE-SAVING TREATMENTS AND CRITICAL DRUGS WITH EXPANDED PHARMACEUTICAL GLASS PACKAGING PORTFOLIO

Corning Incorporated | November 19, 2021

news image

Corning Incorporated introduced Corning Velocity® Vials, specially engineered Type I borosilicate vials externally coated with the company’s proprietary technology, which are helping industry-leading drugmakers respond to the pandemic at speed. The increased efficiency and throughput enabled by Velocity Vials can drive faster manufacturing of COVID-19 vaccines, helping address industry supply chain challenges and meet global demand. Velocity Vials can deliver better econ...

Read More

PHARMA TECH

PHIO PHARMACEUTICALS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2020 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

Phio Pharmaceuticals Corp | October 26, 2020

news image

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually...

Read More

MedCity News | April 14, 2020

news image

BEIGENE REPORTS POSITIVE PHASE III INTERIM ANALYSIS FOR LUNG CANCER DRUG

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with ...

Read More

PHARMACY MARKET

Yangtze River Pharmaceutical, TraceLink | May 06, 2021

news image

YANGTZE RIVER PHARMACEUTICAL GROUP SELECTS TRACELINK PLATFORM FOR GLOBAL COMPLIANCE

TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, incl...

Read More

PHARMA TECH

Corning Incorporated | November 19, 2021

news image

CORNING ACCELERATES DELIVERY OF LIFE-SAVING TREATMENTS AND CRITICAL DRUGS WITH EXPANDED PHARMACEUTICAL GLASS PACKAGING PORTFOLIO

Corning Incorporated introduced Corning Velocity® Vials, specially engineered Type I borosilicate vials externally coated with the company’s proprietary technology, which are helping industry-leading drugmakers respond to the pandemic at speed. The increased efficiency and throughput enabled by Velocity Vials can drive faster manufacturing of COVID-19 vaccines, helping address industry supply chain challenges and meet global demand. Velocity Vials can deliver better econ...

Read More

PHARMA TECH

Phio Pharmaceuticals Corp | October 26, 2020

news image

PHIO PHARMACEUTICALS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2020 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually...

Read More